# PTPRD

Source: https://onco.cc/targets/ptprd/  
OnCo record `ptprd` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.

## Summary

Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2.

CIViC holds 4 clinical evidence items and 0 assertions across 5 variants, naming Temsirolimus, IGF1R Monoclonal Antibody, JSI-124 and Teprotumumab and others. IntOGen calls it a driver in 12 cohorts (8 activating, 4 loss-of-function), covering Invasive Breast Carcinoma, Oesophagogastric Adenocarcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Lymphoid Neoplasm, Melanoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein tyrosine phosphatase receptor type D; Receptor-type tyrosine-protein phosphatase delta
- Tags: cancer-genes-wave
- Symbol: PTPRD
- Class: enzyme
- Biology: Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2. Location: Membrane (UniProt). Locus 9p24.1-p23 (HGNC).
- Where found: Breast cancer: IntOGen driver in 2 cohorts (BRCA); Oesophageal cancer: IntOGen driver in 2 cohorts (ESCA, ESCC); Non-Hodgkin lymphoma: IntOGen driver in 2 cohorts (LNM, NHL); Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (EGC); Ovarian cancer: IntOGen driver in 1 cohort (OVT); Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 5 therapies; IntOGen calls it an activating (Act) driver in 8 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Head And Neck Carcinoma; Ewing Sarcoma Of Bone.

## Sources

- HGNC HGNC:9668: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9668
- UniProt P23468: https://www.uniprot.org/uniprotkb/P23468/entry
- NCBI Gene 5789: https://www.ncbi.nlm.nih.gov/gene/5789
- Ensembl ENSG00000153707: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153707

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small intestine cancer (small bowel adenocarcinoma)](https://onco.cc/cancers/small-bowel/)

---
JSON: https://onco.cc/api/v1/entities/ptprd.json